Question 1

What is AC01?

Accepted Answer

AC01 is a Other.

Question 2

How often does AC01 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 12 articles.

Question 3

When was AC01 first tracked by Ergen?

Accepted Answer

First tracked on Jun 24, 2026.

Question 4

When was AC01 last mentioned in news?

Accepted Answer

Last active on Jun 25, 2026.

Question 5

What is AC01's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AC01 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AC01?

Accepted Answer

AnaCardio AC01 GOAL-HF1 Study Published (Jun 24, 2026, 12 articles).

Question 8

How did the "AnaCardio AC01 GOAL-HF1 Study Published" event impact AC01?

Accepted Answer

AC01 is AnaCardio's lead drug candidate, an oral calcium-sensitising contractile agent, which showed a favorable safety profile and improvements in cardiac function in the GOAL-HF1 study, indicating its potential as a chronic treatment for HFrEF patients.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.